B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres

Ioannou, Yiannis; Lambrianides, Anastasia; Cambridge, G; Leandro, Maria; Edwards, Jonathan; Isenberg, David

doi:10.1136/ard.2007.078402

Cited by 40 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hydroxychloroquine has been suggested to reduce the risk of thrombosis, possibly due to the inhibition of platelet aggregation and [148] is associated with a lower prevalence of positivity lupus anticoagulant or anticardiolipin antibodies. Furthermore, a small observational study of 32 adult patients with antiphospholipid syndrome and SLE treated with rituximab showed a significant reduction in levels of anticardiolipin antibodies [149].…”

Section: Antiphospholipid Syndromementioning

confidence: 99%

Why are kids with lupus at an increased risk of cardiovascular disease?

2015

View full text Add to dashboard Cite

Juvenile-onset systemic lupus erythematosus (SLE) is an aggressive multisystem autoimmune disease. Despite improvements in outcomes for adult patients, children with SLE continue to have a lower life expectancy than adults with SLE, with more aggressive disease, a higher incidence of lupus nephritis and there is an emerging awareness of their increased risk of cardiovascular disease (CVD). In this review, we discuss the evidence for an increased risk of CVD in SLE, its pathogenesis, and the clinical approach to its management.

show abstract

Section: Antiphospholipid Syndromementioning

confidence: 99%

Why are kids with lupus at an increased risk of cardiovascular disease?

2015

View full text Add to dashboard Cite

show abstract

“…Testing for antibodies to CL is routinely performed as one of a panel of tests for autoimmune disorders (2). In our studies, the presence of ACA at relatively high titers in patients with CFS suggests the possibility of alterations to the inner membranes of liver mitochondria, thereby exposing CL in a manner so as to elicit an antibody response to CL.…”

Section: Introductionmentioning

confidence: 82%

Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome

Hokama

Campora

Hara

et al. 2009

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Examination of anticardiolipin antibodies (ACAs) in the sera of patients clinically diagnosed with chronic fatigue syndrome (CFS) using an enzyme-linked immunoassay procedure demonstrated the presence of immunoglobulin M isotypes in 95% of CFS serum samples tested. The presence of immunoglobulin G and immunoglobulin A isotypes were also detected in a subset of the samples. Future studies will focus on elucidating whether alterations to mitochondrial inner membranes and/or metabolic functions play a possible role in the expression of ACAs.

show abstract

“…Rituximab has been shown to decrease the titres of aPLs and, therefore, should decrease the thrombotic risk of patients with APS [106]. Thus, Ioannou and colleagues [107] reported a major fall in IgG aCL titres in seven SLE patients who had received treatment with rituximab and CYC. Moreover, 8 out of 12 APS patients treated with rituximab due to recurrent thrombosis or refractory thrombocytopenia showed normalization or a reduction in aPL titres [108].…”

Section: Biologic Therapymentioning

confidence: 98%

Kidney disease in primary anti-phospholipid antibody syndrome

Gracia-Tello

Isenberg

2016

Rheumatology

View full text Add to dashboard Cite

APS is an autoimmune disease defined by the presence of arterial or venous thrombotic events and/or pregnancy morbidity in patients who test positive for aPL. APS can be isolated (primary APS) or associated with other autoimmune diseases. The kidney is a major target organ in APS, and renal thrombosis can occur at any level within the vasculature of the kidney (renal arteries, intrarenal vasculature and renal veins). Histological findings vary widely, including ischaemic glomeruli and thrombotic lesions without glomerular or arterial immune deposits on immunofluorescence. Renal involvement in patients with definite APS is treated with long-term anticoagulants as warfarin, but new treatments are being tried. The aim of this article is to review the links between primary APS and kidney disease.

show abstract

B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres

Abstract: This small observational study in patients with SLE is the first to demonstrate that BCDT results in a significant reduction in levels of IgG aCL.

Cited by 40 publications

References 14 publications

Why are kids with lupus at an increased risk of cardiovascular disease?

Why are kids with lupus at an increased risk of cardiovascular disease?

Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome

Kidney disease in primary anti-phospholipid antibody syndrome

Contact Info

Product

Resources

About